Neuralstem, Inc.  

(Public, NYSEMKT:CUR)   Watch this stock  
Find more results for NYSEAMEX:CUR
+0.07 (2.66%)
Dec 24 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 2.55 - 2.72
52 week 2.12 - 4.81
Open 2.63
Vol / Avg. 181,649.00/461,063.00
Mkt cap 235.87M
P/E     -
Div/yield     -
EPS -0.24
Shares 87.36M
Beta 1.46
Inst. own 20%
Mar 9, 2015
Q4 2014 Neuralstem Inc Earnings Release (Estimated) Add to calendar
Nov 7, 2014
Q3 2014 Neuralstem Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -89104.80% -18028.96%
Operating margin -82135.00% -11384.64%
EBITD margin - -11162.67%
Return on average assets -57.58% -140.83%
Return on average equity -79.54% -257.71%
Employees 15 -
CDP Score - -


9700 Great Seneca Highway
United States - Map
+1-301-3664841 (Phone)
+1-302-7301370 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Neuralstem, Inc. is a development-stage company focused on the development and commercialization of treatments for central nervous system disease based on transplanting human neural stems cells and the use of small molecule drugs. The Company has developed and maintains a portfolio of patents and patent applications that form base for its research and development efforts in the area of neural stem cell research. The Company's focus is the development of methods to generate replacement cells from neural stem cells. During the year ended December 31, 2011, the Company was selected as the primary subcontractor for the United States Department of Defense (DOD) contract to develop human neural stem cell technology for the treatment of cancerous brain tumors. The Company commenced work on the project in May 2011.

Officers and directors

Karl Johe Ph.D. Chairman of the Board, Chief Scientific Officer
Age: 53
Bio & Compensation  - Reuters
I. Richard Garr J.D. President, Chief Executive Officer, Chief Financial Officer, General Counsel, Director
Age: 61
Bio & Compensation  - Reuters
Sandford Drexel Smith Director
Age: 67
Bio & Compensation  - Reuters
Scott V. Ogilvie Independent Director
Age: 58
Bio & Compensation  - Reuters
William C. Oldaker Independent Director
Age: 72
Bio & Compensation  - Reuters
Catherine Angell Sohn Independent Director
Age: 61
Bio & Compensation  - Reuters
Stanley I. Westreich Independent Director
Age: 75
Bio & Compensation  - Reuters